Psychopharmacology research for individuals with mental retardation: methodological issues and suggestions

Matson, Johnny L.; Bielecki, JoAnne; Mayville, Stephen B.; Matson, Michael L.

doi:10.1016/s0891-4222(03)00030-1

Cited by 38 publications

(20 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A range of studies have investigated prescribing patterns of psycholeptic and anticonvulsant drugs in people with ID (Hogg 1992; Matson et al. 2003; Holden & Gitlesen 2004; Valdovinos et al.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The documentation of health problems in relation to prescribed medication in people with profound intellectual and multiple disabilities

Heide

Putten

Berg

et al. 2009

J intellect Disabil Res

View full text Add to dashboard Cite

The best level of documentation was found for anticonvulsants the worst for drugs for peptic ulcer and gastro-oesophageal reflux disease. Lack of documenting an indication may be due to off-label use, inadvertent continuation of no longer indicated medication, inadequate documentation and underdiagnosis. Adequate documentation practices are essential because of the communication problems that are characteristic for persons with PIMD.

show abstract

Section: Introductionmentioning

confidence: 99%

“…2005). These studies raised concern about the quality of prescribing of psychotropic medication in this group (Matson et al. 2003).…”

Section: Introductionmentioning

confidence: 99%

The documentation of health problems in relation to prescribed medication in people with profound intellectual and multiple disabilities

Heide

Putten

Berg

et al. 2009

J intellect Disabil Res

View full text Add to dashboard Cite

show abstract

“…There continues to be a predisposition to choose psychopharmacological interventions over behavioural, social or educational interventions, however. It is our opinion that medication‐based interventions can be used in harmony with behavioural interventions and in fact, behavioural research can provide guidance to the determination of treatment efficacy (Matson et al . 2003; Thompson et al .…”

Section: Introductionmentioning

confidence: 99%

“…who are ‘blind’) will avoid some of these problems. Finally, during a medication trial all other interventions should be kept the same to control for the confounding effects of multiple interventions (Matson et al . 2003).…”

Section: Introductionmentioning

confidence: 99%

Measurement of problem behaviour during medication evaluations

Zarcone

Valdovinos

2008

J intellect Disabil Res

View full text Add to dashboard Cite

Background The focus of this review is on methods that are currently being used to evaluate the behavioural effects of medication for individuals with intellectual disabilities. First we describe what has been identified as the ideal criteria for conducting clinical trials and how these criteria may be adapted to do less controlled evaluations. The central theme is a review of the biological measures (e.g. labs, drug levels), behavioural rating scales and direct observation measures that are often used to evaluate medication effects. Issues related to how the side effects of medication can affect behaviour will also be discussed. Conclusion The importance of encouraging communication and collaboration across all systems of care and the use of socially valid measures are discussed.

show abstract

“…In the last few decades a broad range of medications have been tried . These are very restrictive interventions, they are not targeting specific behaviors and severe and often chronic side effects are common (Advokat, Mayville, & Matson, 2000;Matson, Bielecki, Mayville, & Matson, 2003;Singh, Matson, Cooper, Dixon, & Sturmey, 2005). Having noted these factors, and questionable efficacy in some cases, the use of these drugs for persons with ASD is increasing.…”

mentioning

confidence: 99%